BioStock: CombiGene strives for a broader pipeline

In 2021, Swedish gene therapy company CombiGene signed an exclusive, global license agreement for candidate CG01 with Spark Therapeutics, which entitles CombiGene to up to 328.5 million USD excluding royalties. The parties are now putting the finishing touches on the preclinical work, after which Spark will be responsible for and pay for the first clinical studies in patients with drug-resistant focal epilepsy.

Read the full article about CombiGene at biostock.se:

https://www.biostock.se/en/2022/04/combigene-strives-for-a-broader-pipeline/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/